|
[1]
|
Mocarzel, L.O., Bicca, J., Jarske, L., et al. (2016) Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome. Case Reports in Gastroenterology, 10, 531-537. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Basili, S., Pastori, D., Raparelli, V., et al. (2018) Anticoagulant Therapy in Patients with Liver Cirrhosis and Portal Vein Thrombosis: Insights for the Clinician. Therapeutic Advances in Gastroen-terology, 11, 1756284818793561. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Gîrleanu, I., Trifan, A., Stanciu, C., et al. (2018) Portal Vein Thrombosis in Cirrhotic Patients—It Is Always the Small Pieces that Make the Big Picture. World Journal of Gastroen-terology, 24, 4419-4427. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Lankarani, K.B., Homayon, K., Motevalli, D., et al. (2015) Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran. Hepatitis Monthly, 15, e26407. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Zafar, M., Heslop-Harrison, W., Loterh, L., et al. (2022) Splenic Vein Thrombosis: A Case Series of Consequential Chronic Pancreatitis and Sequential Myeloproliferative Disorder. Cu-reus, 14, e25924. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Xian, J., Tang, Y., Shao, H., et al. (2021) Effect of Portal Vein Throm-bosis on the Prognosis of Patients with Cirrhosis without a Liver Transplant: A Systematic Review and Meta-Analysis. Medicine, 100, e25439. [Google Scholar] [CrossRef]
|
|
[7]
|
Senzolo, M., Piano, S., Shalaby, S., et al. (2021) Compari-son of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. The American Journal of Medicine, 134, 1278-1285. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
EASL (2016) EASL Clinical Practice Guidelines: Vascular Diseases of the Liver. Journal of Hepatology, 64, 179-202. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Northup, P.G., Garcia-Pagan, J.C., Garcia-Tsao, G., et al. (2021) Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients with Liver Disease: 2020 Prac-tice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 73, 366-413. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Beyer-Westendorf, J. and Marten, S. (2021) Reproductive Issues in Women on Direct Oral Anticoagulants. Research and Practice in Thrombosis and Haemostasis, 5, e12512. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Marcucci, M., Etxeandia-Ikobaltzeta, I., Yang, S., et al. (2022) Benefits and Harms of Direct Oral Anticoagulation and Low Molecular Weight Heparin for Thromboprophylaxis in Patients Under-going Non-Cardiac Surgery: Systematic Review and Network Meta-Analysis of Randomised Trials. BMJ, 376, e066785. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Anderson, D.R., Morgano, G.P, Bennett, C., et al. (2019) American Society of Hematology 2019 Guidelines for Management of Venous Thromboembolism: Prevention of Venous Throm-boembolism in Surgical Hospitalized Patients. Blood Advances, 3, 3898-3944. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Imberti, D., Pomero, F. and Mastroiacovo, D. (2020) Di-rect Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Insights from the EINSTEIN CHOICE Study. Blood Transfusion, 18, 49-57.
|
|
[14]
|
De Franchis, R., Bosch, J., Garcia-Tsao, G., et al. (2022) Baveno VII-Renewing Consensus in Portal Hypertension. Journal of Hepatology, 76, 959-974. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
O’Leary, J.G., Greenberg, C.S., Patton, H.M., et al. (2019) AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology, 157, 34-43.E1. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Ponziani, F.R., De Stefano, V. and Gasbarrini, A. (2009) Viral Cirrhosis: An Overview of Haemostatic Alterations and Clinical Consequences. Mediterranean Journal of Hematology and Infectious Diseases, 1, e2009033. [Google Scholar] [CrossRef]
|
|
[17]
|
Mcconnell, M.J., Kondo, R., Kawaguchi, N., et al. (2022) Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. Hepatology Communi-cations, 6, 255-269. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Xu, S., Guo, X., Yang, B., et al. (2021) Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clinical and Translational Gastroenterology, 12, e00409. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Leonardi, F., Maria, N.D. and Villa, E. (2017) Anticoagula-tion in Cirrhosis: A New Paradigm? Clinical and Molecular Hepatology, 23, 13-21. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Wang, L., Guo, X., Xu, X., et al. (2021) Anticoagulation Favors Thrombus Recanalization and Survival in Patients with Liver Cirrhosis and Portal Vein Thrombosis: Results of a Me-ta-Analysis. Advances in Therapy, 38, 495-520. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Llop, E. and Seijo, S. (2016) Treatment of Non-Cirrhotic, Non-Tumoural Portal Vein Thrombosis. Gastroenterology & Hepatology, 39, 403-410. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Deleve, L.D., Valla, D.C. and Garcia-Tsao, G. (2009) Vascu-lar Disorders of the Liver. Hepatology, 49, 1729-1764. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Simonetto, D.A., Singal, A.K., Garcia-Tsao, G., et al. (2020) ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. The American Journal of Gastroenterology, 115, 18-40. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology and Chinese Medical Association (2020) Consensus for Management of Portal Vein Thrombosis in Liver Cirrhosis (2020, Shanghai). Journal of Digestive Diseases, 22, 176-186.
|
|
[25]
|
Priyanka, P., Kupec, J.T., Krafft, M., et al. (2018) Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. International Journal of Hepatology, 2018, Article ID: 8432781. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Steffel, J., Verhamme, P., Potpara, T.S., et al. (2018) The 2018 Euro-pean Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. European Heart Journal, 39, 1330-1393. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Konstantinides, S.V., Meyer, G., Becattini, C., et al. (2019) 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaborate on with the European Respiratory Society (ERS): The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). European Respiratory Journal, 54, Article 1901647. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Agnelli, G., Buller, H.R., Cohen, A., et al. (2013) Oral Apixa-ban for the Treatment of Acute Venous Thromboembolism. The New England Journal of Medicine, 369, 799-808. [Google Scholar] [CrossRef]
|
|
[29]
|
Schulman, S., Kakkar, A.K., Goldhaber, S.Z., et al. (2014) Treat-ment of Acute Venous Thromboembolism with Dabigatran or Warfarin and Pooled Analysis. Circulation, 129, 764-772. [Google Scholar] [CrossRef]
|
|
[30]
|
Hokusai, V.T.E.I., Buller, H.R., Decousus, H., et al. (2013) Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. The New England Journal of Medicine, 369, 1406-1415. [Google Scholar] [CrossRef]
|
|
[31]
|
Ng, C.H., Tan, D.J.H., Nistala, K.R.Y., et al. (2021) A Network Meta-Analysis of Direct Oral Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Hepatology International, 15, 1196-1206. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Mohan, B.P., Aravamudan, V.M., Khan, S.R., et al. (2020) Treatment Response and Bleeding Events Associated with Anticoagulant Therapy of Portal Vein Thrombosis in Cirrhotic Patients: Systematic Review and Meta-Analysis. Annals of Gastroenterology, 33, 521-527. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Davis, k.A., Joseph, J. and Nisly, S.A. (2020) Direct Oral Anticoag-ulants and Warfarin in Patients with Cirrhosis: A Comparison of Outcomes. Journal of Thrombosis and Thrombolysis, 50, 457-461. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Ghazaleh, S., Beran, A., Aburayyan, K., et al. (2021) Efficacy and Safety of Anticoagulation in Non-Malignant Portal Vein Thrombosis in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. Annals of Gastroenterology, 34, 104-110. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Salerno, D.M., Tsapepas, D., Papachristos, A., et al. (2017) Direct Oral Anticoagulant Considerations in Solid Organ Transplantation: A Review. Clinical Transplantation, 31, e12873. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Kubitza, D., Roth, A., Becka, M., et al. (2013) Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of a Single Dose of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor. British Journal of Clinical Pharmacology, 76, 89-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Graff, J. and Harder, S. (2013) Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment. Clinical Pharmacokinetics, 52, 243-254. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Violi, F., Loffredo, L. and Pastori, D. (2021) Anticoagulation in Patients with Advanced Liver Disease: An Open Issue. Internal and Emergency Medicine, 16, 61-71. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Harder, S. (2014) Pharmacokinetic and Pharmacodynamic Eval-uation of Rivaroxaban: Considerations for the Treatment of Venous Thromboembolism. Thrombosis Journal, 12, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Ufer, M. (2010) Comparative Efficacy and Safety of the Novel Oral Anticoagulants Dabigatran, Rivaroxaban and Apixaban in Preclinical and Clinical Development. Thrombosis and Haemostasis, 103, 572-585. [Google Scholar] [CrossRef]
|
|
[41]
|
Kvasnicka, T., Malikova, I., Zenahlikova, Z., et al. (2017) Rivaroxa-ban-Metabolism, Pharmacologic Properties and Drug Interactions. Current Drug Metabolism, 18, 636-642. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Willmann, S., Zhang, L., Frede, M., et al. (2018) Inte-grated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations. CPT: Pharmacomet-rics & Systems Pharmacology, 7, 309-320. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Lv, Y., Bai, W., Li, K., et al. (2021) Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Pro-spective Observational Study. The American Journal of Gastroenterology, 116, 1447-1464. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Hanafy, A.S., Abd-Elsalam, S. and Dawoud, M.M. (2019) Randomized Controlled Trial of Rivaroxaban versus Warfarin in the Management of Acute Non-Neoplastic Portal Vein Thrombosis. Vascular Pharmacology, 113, 86-91. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Raymond, J., Imbert, L., Cousin, T., et al. (2021) Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. Journal of Personalized Medicine, 11, Article 37. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Kanuri, S.H. and Kreutz, R.P. (2019) Pharmacogenomics of Novel Di-rect Oral Anticoagulants: Newly Identified Genes and Genetic Variants. Journal of Personalized Medicine, 9, Article 7. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Gomez-Outes, A., Suarez-Gea, M.L., Lecumberri, R., et al. (2013) Po-tential Role of New Anticoagulants for Prevention and Treatment of Venous Thromboembolism in Cancer Patientsz. Vascular Health and Risk Management, 9, 207-228. [Google Scholar] [CrossRef]
|
|
[48]
|
Aryal, M.R., Gosain, R., Donato, A., et al. (2019) Systematic Review and Meta-Analysis of the Efficacy and Safety of Apixaban Compared to Rivaroxaban in Acute VTE in the Real World. Blood Advances, 3, 2381-2387. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Mookadam, M., Shamoun, F.E., Ramakrishna, H., et al. (2015) Perioperative Venous Thromboembolic Disease and the Emerging Role of the Novel Oral Anticoagulants: An Analysis of the Implications for Perioperative Management. Annals of Cardiac Anaesthesia, 18, 517-527. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Pruszczyk, P., Tomaszuk-Kazberuk, A., Slowik, A., et al. (2017) Management of Bleeding or Urgent Interventions in Patients Treated with Direct Oral Anticoagulants: 2017 Recommen-dations for Poland. Polish Archives of Internal Medicine, 127, 343-351. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Nagaoki, Y., Aikata, H., Daijyo, K., et al. (2018) Efficacy and Safety of Edoxaban for Treatment of Portal Vein Thrombosis Following Danaparoid Sodium in Patients with Liver Cirrhosis. Hepatology Research, 48, 51-58. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Blech, S., Ebner, T., Ludwig-Schwellinger, E., et al. (2008) The Metabo-lism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. Drug Metabolism & Disposition, 36, 386-399. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Burstein, B., Wieruszewski, P.M., Zhao, Y.J., et al. (2019) Antico-agulation with Direct Thrombin Inhibitors during Extracorporeal Membrane Oxygenation. World Journal of Critical Care Medicine, 8, 87-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Naymagon, L., Tremblay, D., Zubizarreta, N., et al. (2020) The Effi-cacy and Safety of Direct Oral Anticoagulants in Noncirrhotic Portal Vein Thrombosis. Blood Advances, 4, 655-666. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Potze, W., Adelmeijer, J. and Lisman, T. (2015) De-creased in Vitro Anticoagulant Potency of Rivaroxaban and Apixaban in Plasma from Patients with Cirrhosis. Hepatolo-gy, 61, 1435-1436. [Google Scholar] [CrossRef] [PubMed]
|